Clinical Trial Results - Progress in Cancer Care
These summaries highlight recently released results from cancer clinical trials. The findings are significant enough that they are likely to influence your medical care.
The summaries are listed in reverse chronological order. You may also use the navigation tools on the left to search the summaries by keyword or type of cancer.
- Trials Point to More Treatment Options for Chronic Myeloid Leukemia
(Posted: 07/08/2010) - Two studies published online June 5, 2010, in the New England Journal of Medicine found that two second-generation kinase inhibitors outperform imatinib, at least over the short term, in patients with chronic myelogenous leukemia.
- Adding Radiation to Hormone Therapy Improves Survival in Locally Advanced Prostate Cancer
(Posted: 07/08/2010) - Adding radiotherapy to androgen deprivation therapy (ADT) improves survival in men with locally advanced prostate cancer, according to findings presented at the 2010 ASCO meeting in Chicago.
- Post-Remission Therapy that Includes All-Trans Retinoic Acid is Effective for Acute Promyelocytic Leukemia
(Posted: 07/02/2010) - A study published online April 14, 2010, in Blood finds that modified consolidation therapy regimens that include all-trans retinoic acid may be less toxic and as effective for patients with low- and medium-risk acute promyelocytic leukemia and may reduce relapse rates for patients with high-risk disease.
- Experimental Drug Improves Survival in Advanced Melanoma
(Posted: 06/28/2010) - An experimental drug that targets the immune system, ipilimumab, has helped patients with advanced cases of melanoma live longer than expected, according to results of a large randomized clinical trial presented at the 2010 American Society of Clinical Oncology annual meeting and published June 6, 2010, in the New England Journal of Medicine.
- Heart Problems From Trastuzumab (Herceptin®) Do Not Increase in the Short Term
(Posted: 06/25/2007, Updated: 06/22/2010) - Women with breast cancer who take the drug trastuzumab (Herceptin®) are at risk of heart problems during treatment. Now a study has shown that the incidence of such problems does not increase in the short term, though the long-term effects remain unknown, according to findings presented at the 2007 ASCO meeting in Chicago.